INTRODUCTION AND OBJECTIVES: Actionable genomic alterations include somatic mutations and structural alterations that predict response to targeted drug therapy. Defining the landscape of actionable alterations in bladder cancer may identify therapeutic targets and inform targeted therapy trials in patients with disease unresponsive to Bacillus Calmette-Guerin (BCG) or neoadjuvant chemotherapy (NAC). In this study we describe the prevalence of actionable alterations and the corresponding evidence supporting the alteration as predictive of response to targeted therapy in primary bladder tumors that underwent next-generation sequencing.
INTRODUCTION AND OBJECTIVES: Although recent epidemiologic studies have shown improved oncologic outcomes over time for patients with localized bladder cancer, a large single-center radical cystectomy (RC) series failed to demonstrate improved outcomes over a three-decade experience. Given this conflicting evidence, we sought to assess for changes in survival outcomes, perioperative management, and surgical performance at Memorial Sloan Kettering Cancer Center (MSKCC) over a 21-year period.
METHODS: All patients with urothelial carcinoma who underwent RC at MSKCC from 1995 through 2015 were identified. Analysis of clinicodemographic changes over time was performed. Multivariable models adjusting for age, consensus tumor stage, lymph node (LN) status, and date of RC were generated. Adjusted rates of neoadjuvant chemotherapy (NAC) use and surgical performance including positive soft tissue and urothelial margins, total LN yield, pathologic T0 (pT0) rates, and 5-year rates of disease recurrence and cancer-specific death controlled for consensus stage are reported over time. Estimated rates with 95% confidence intervals (CI) are reported.
RESULTS: The cohort includes 2,911 patients with a median 5.7-year follow-up (quartiles 3.5, 9.9). The distribution of age at RC (median 68 years; quartiles 61, 75) and gender (77% male) showed no significant changes over time (p[0.14 and p[0.3, respectively) . NAC use among patients with muscle-invasive bladder cancer (MIBC) increased from <6% before 2000 to 52% in 2015 (p<0.001), with a corresponding rise in pT0 rates among patients with MIBC from 5.5% (95% CI 2.4%, 12%) in 1995 to 26% (95% CI 18%, 37%) by 2015 (p<0.001). Mean LN yield increased from a mean of 7 LNs in 1995 to 25 in 2015 (p<0.001). Positive soft tissue and urothelial margin rates decreased from 5% and 15% to <1% and 9%, respectively, from 1995 to 2015 (p<0.001, p[0.14) . The adjusted probability of disease recurrence at 5 years decreased from 42% (95% CI 35%, 49%) in 1995 to 30% (95% CI 24%, 35%) in 2015 (p<0.001). The adjusted probability of cancerspecific death at 5 years decreased from 33% (95% CI 26%, 39%) in 1995 to 20% (95% CI 15%, 25%) in 2015 (p<0.001).
CONCLUSIONS: Over a 21-year span, we observed improved oncologic outcomes coinciding with increasing LN yield, negative soft tissue margin rates, use of NAC and pT0 rates, suggesting improvements in perioperative management and surgical performance have resulted in improved oncologic outcomes among patients undergoing RC.
